Keywords: isentress, cuts, viral, load, untreated, patients, drug

Isentress cuts viral load in untreated patients

Article | 03 November 2008

Print This

US drug major Merck & Co's Isentress (raltegravir) reduced HIV viral load to undetectable levels in 86% of patients compared to 82% for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in